Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.51 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991645 | 0.83 | KMT2A (0.50) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL4065318 | 0.83 | KMT2A (0.50) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL13812973 | 0.83 | KMT2A (0.50) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL27225170 | 0.82 | KMT2A (0.49) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL22184593 | 0.81 | KMT2A (0.51) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL574174 | 0.81 | KMT2A (0.51) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL24496115 | 0.80 | KMT2A (0.47) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL22184570 | 0.80 | KMT2A (0.47) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL6944883 | 0.80 | KMT2A (0.47) | GABBR2GABBR1KMT2AMEN1CYP1A2 | |
| SCHEMBL4712427 | 0.80 | KMT2A (0.50) | GABBR2GABBR1KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | NUAK1, NUAK2, NEK11 | GABBR2 4200/4885GABBR1 4278/4885KMT2A 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.